(Q44035116)

29 November 2017

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder (English)

1 reference

29 November 2017

Kreder K

1

1 reference

29 November 2017

Mayne C

series ordinal

2

1 reference

29 November 2017

Jonas U

series ordinal

3

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

41

1 reference

29 November 2017

6

1 reference

29 November 2017

588-595

1 reference

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900177-X

7 January 2021

10.1016/S0302-2838(02)00177-X

Identifiers

DOI

1 reference

29 November 2017

1 reference